Fragner Michael L, Parikh Manish A, Jackson Kaedrea A, Schwartzman Michal Laniado, Frishman William H, Peterson Stephen J
From the Department of Medicine, New York Presbyterian Brooklyn Methodist Hospital, Brooklyn, NY.
Weill Department of Medicine, Weill Cornell Medicine, New York, NY.
Cardiol Rev. 2024 May 2. doi: 10.1097/CRD.0000000000000711.
Metabolic syndrome increases the risk of stroke, cardiovascular disease, and diabetes. The morbidity and mortality associated with this constellation of risk factors are equally alarming when considering the economic and global significance that this epidemic has on an institutional and patient level. Despite several current treatments available, there needs to be a continuous effort to explore more specific and effective druggable entities for preventative and therapeutic interventions. Within this context, the G-protein coupled receptor, GPR75, is an attractive pharmacological target. GPR75 and its association with its ligand, 20-hydroxyeicosatetraenoic acid, have been shown to promote hypertension, inflammation, obesity, and insulin resistance. This review will help shed light on this novel signaling pathway and offer a perspective on a promising new direction of targeting different aspects of the metabolic syndrome involving GPR75. Gene targeting of GPR75 is more effective than current pharmacologic therapies without the known side effects.
代谢综合征会增加中风、心血管疾病和糖尿病的风险。考虑到这一流行病在机构和患者层面上的经济和全球意义，与这一系列风险因素相关的发病率和死亡率同样令人担忧。尽管目前有几种治疗方法，但仍需要持续努力探索更具特异性和有效性的可成药靶点，用于预防和治疗干预。在此背景下，G蛋白偶联受体GPR75是一个有吸引力的药理学靶点。GPR75及其与配体20-羟基二十碳四烯酸的关联已被证明会促进高血压、炎症、肥胖和胰岛素抵抗。本综述将有助于阐明这一新的信号通路，并就靶向涉及GPR75的代谢综合征不同方面的一个有前景的新方向提供观点。GPR75的基因靶向治疗比目前的药物治疗更有效，且没有已知的副作用。
